PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28890776-4	2017	Interestingly the observed SAR was not in complete agreement with the commonly observed binding mode where the pyrazolo[3,4-d]pyrimidine compounds are bound in a similar fashion as PKD"s natural ligand ATP.	Adenosine Triphosphate	202-205	sarcosine dehydrogenase	Homo sapiens	27-30	
22169260-0	2012	A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors.	Adenosine Triphosphate	145-148	sarcosine dehydrogenase	Homo sapiens	126-129	
23058106-1	2012	Two closely related binding modes have previously been proposed for the ATP-competitive benzimidazole class of checkpoint kinase 2 (CHK2) inhibitors; however, neither binding mode is entirely consistent with the reported SAR.	Adenosine Triphosphate	72-75	sarcosine dehydrogenase	Homo sapiens	221-224	
23058106-2	2012	Unconstrained rigid docking of benzimidazole ligands into representative CHK2 protein crystal structures reveals an alternative binding mode involving a water-mediated interaction with the hinge region; docking which incorporates protein side chain flexibility for selected residues in the ATP binding site resulted in a refinement of the water-mediated hinge binding mode that is consistent with observed SAR.	Adenosine Triphosphate	290-293	sarcosine dehydrogenase	Homo sapiens	406-409	
20153189-1	2010	The SAR of PXR transactivation by 3-(benzimidazol-2-yl)-pyridine-2-one based ATP competitive inhibitors of Insulin-like Growth Factor 1 Receptor kinase (IGF-1R) is discussed.	Adenosine Triphosphate	77-80	sarcosine dehydrogenase	Homo sapiens	4-7	
20053762-6	2010	SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC(50) of 13.3 nmol/L on the isolated human enzyme.	Adenosine Triphosphate	17-20	sarcosine dehydrogenase	Homo sapiens	0-3	
11741479-5	2001	By constructing diarylurea informer libraries based on the structural requirements of Cdk inhibitors in the ATP binding pocket of the Cdk4 model, we were able to identify a potent Cdk4 inhibitor N-(9-oxo-9H-fluoren-4-yl)-N"-pyridin-2-ylurea 15 (IC(50) = 0.10 microM), together with preliminary SAR.	Adenosine Triphosphate	108-111	sarcosine dehydrogenase	Homo sapiens	294-297